A six-year-old girl from Stevenage has regained her vision through a revolutionary gene therapy treatment, offering new hope for children suffering from a rare genetic condition that leads to blindness. Saffie Sandford, who was diagnosed with Leber's Congenital Amaurosis, can now see normally in both daylight and low-light conditions following the groundbreaking intervention.
Leber's Congenital Amaurosis, known as LCA, results from a mutation in the RPE 65 gene. Both of Saffie's parents unknowingly carried a copy of this defective gene. The condition typically manifests in children as severe difficulty seeing in low light and impaired daylight vision. Without treatment, the progressive disorder leads to complete blindness by early adulthood.
The challenge with diagnosing LCA lies in the limitations of testing very young children. Because infants and toddlers cannot participate in traditional eyesight examinations, diagnosis often comes late despite the condition's progression beginning at birth. This delay can prove critical as the disease steadily worsens over time.
Saffie's fortune changed when she was referred from Moorfields Eye Hospital in Herefordshire to Great Ormond Street Hospital Children's Trust in London. The facility had been developing a novel gene therapy specifically designed to combat this condition. The treatment, called Luxturna, delivers a healthy copy of the RPE 65 gene directly into both eyes through a single-dose procedure.
Saffie received her first treatment in April 2025, followed by the second dose in September of the same year. The results have proven transformative for the young girl and her family.
"Having the treatment has been life-changing, it's like someone waved a magic wand and restored her sight in the dark," said Saffie's mother, Lisa. "We've been able to take her trick or treating, and out to restaurants in the evening—something that was impossible before."
The improvements extend beyond nighttime vision. Lisa noted that her daughter's peripheral sight in daylight has also improved significantly. "She's now able to see hazards and has improved at school. She's thriving and you wouldn't know she had the condition just by looking at her," she explained.
Great Ormond Street Hospital recently published a comprehensive study examining the effects of Luxturna, which the institution developed in partnership with Moorfields. The research involved children ranging from fifteen months to twelve years of age who had been diagnosed with LCA. The findings demonstrated remarkable success, with seven out of ten children showing clinically meaningful improvements in vision following the Luxturna treatment.
The study's evidence included both parental testimonials and objective medical data. Researchers employed a specialized new test that measures electrical signals transmitted from the retina to the brain, providing a harmless and innovative method for assessing vision in infants who cannot participate in conventional eye examinations.
Rob Henderson, consultant ophthalmologist at Great Ormond Street Hospital, emphasized the significance of these findings. "For the first time, we've been able to show objectively that gene therapy can strengthen the visual pathways in babies and young children who are living with this rare eye condition," he stated.
Henderson further noted the profound impact even modest improvements can have on affected families. "For many of the families we work with, even small improvements in their child's ability to see the world around them make a profound difference," he said.
The success of Luxturna represents a significant advancement in pediatric ophthalmology and gene therapy. For families facing the devastating prospect of childhood blindness, treatments like this offer not merely medical intervention but the restoration of fundamental experiences—from navigating a darkened room to participating in evening activities that most families take for granted. Saffie's story illustrates how cutting-edge medical research can translate into tangible, life-altering outcomes for young patients and their families.